A5014493498- Ovarian cancer diagnosis and treatment
- PARP inhibition in cancer therapy
- Endometrial and Cervical Cancer Treatments
- BRCA gene mutations in cancer
- Cancer Immunotherapy and Biomarkers
- Colorectal and Anal Carcinomas
- Cancer Genomics and Diagnostics
- Lymphoma Diagnosis and Treatment
- Sarcoma Diagnosis and Treatment
- Economic and Financial Impacts of Cancer
- Intraperitoneal and Appendiceal Malignancies
- HER2/EGFR in Cancer Research
- Toxin Mechanisms and Immunotoxins
- Lung Cancer Research Studies
- Circular RNAs in diseases
- Cervical Cancer and HPV Research
- Cancer-related molecular mechanisms research
- Family Dynamics and Relationships
- Genital Health and Disease
- Urticaria and Related Conditions
- Chemotherapy-related skin toxicity
- Cell death mechanisms and regulation
- Advanced Breast Cancer Therapies
- Colorectal Cancer Treatments and Studies
- Drug-Induced Adverse Reactions
National Cancer Institute
2023-2024
Agostino Gemelli University Polyclinic
2021-2024
Istituti di Ricovero e Cura a Carattere Scientifico
2021-2024
Azienda Ospedaliera San Giovanni Addolorata
2024
National Institutes of Health
2023-2024
Center for Cancer Research
2023-2024
Università Cattolica del Sacro Cuore
2020-2023
Hospital of Prato
2023
Vatican Observatory
2023
Herlev Hospital
2016
Platinum-resistant ovarian cancer patients have a poor prognosis and few treatment options are available. Preclinical clinical data demonstrated that the combination of poly-ADP ribose polymerase inhibitors with immune checkpoint could synergistic antitumor activity in this setting patients.The primary objective is to assess efficacy niraparib plus dostarlimab compared chemotherapy recurrent not suitable for platinum treatment.This trial will hypothesis therapy effective increase overall...
Introduction: Pembrolizumab is an immune checkpoint inhibitor with high specificity for binding to the programmed cell death 1 (PD-1) receptor. It has been approved by FDA in patients recurrent or metastatic cervical cancer disease progression on after chemotherapy whose tumors express ligand (PD-L1).Areas covered: Clinical studies of pembrolizumab were analyzed and discussed. Data obtained searching English peer-reviewed articles PubMed, clinical trials registered clincaltrials.gov related...
Purpose of review Epithelial ovarian cancer (EOC) is the fifth cause death among women, and 70–80% patients relapse within 2 years from last cycle first-line chemotherapy despite a complete response to optimal debulking surgery. In this context, goal maintenance treatment strategy prolong time recurrence. The recent development targeted molecular therapies resulted in broader spectrum therapeutic options with consequent higher clinical benefit but less toxicity. This summarizes currently...
Correlation between BRCA1/2 (BRCA) pathogenic variants and the response to poly (ADP-ribose) polymerase inhibitors (PARPi) has been recognized in patients with ovarian cancer. Moreover, data on clinical implications of unknown significance are lacking. The aim this study was evaluate differences survival outcomes BRCA significance, mutated, wild type relapsed cancer treated PARPi.Patients whose somatic testing available who were receiving PARPi as maintenance treatment at first recurrence...
Next-generation sequencing (NGS) analysis has become an essential tool for endometrial carcinoma management. Moreover, molecular-driven therapies play increasingly remarkable role in the era of precision oncology. This study aims to determine clinical relevance NGS testing management by analyzing benefit NGS-driven targeted therapies.A single-center retrospective was conducted on 25 patients who underwent Foundation Medicine CDx assay at Fondazione Policlinico Universitario Agostino Gemelli,...
Parenting coordination is emerging in numerous countries around the globe as a response to need protect children families whose parents experience high conflict following their separation or divorce. This article describes different trends implementation of parenting programs Canada, Spain, and Italy socio‐legal contexts which they have evolved. An analysis will also be presented unique challenges faced by these ensuing debates on issues related referral process, legal procedures,...
<h3>Introduction/Background</h3> Little is known about correlations between the type and location of BRCA1/2 mutations magnitude response to Poly (ADP-ribose) polymerase inhibitors (PARPi) in advanced ovarian cancer (OC), as maintenance. <h3>Methodology</h3> This retrospective study enrolled patients with newly diagnosed BRCA-mutated high-grade serous or endometrioid OC who received PARPi maintenance alone after first-line chemotherapy. Progression-free survival (PFS), time interval last...
<h3>Introduction/Background</h3> Homologous Recombination deficiency (HRd) testing is an essential tool to tailor the maintenance treatment strategy after first-line, platinum-based chemotherapy for advanced high-grade ovarian cancer (aHGOC) patients. Bevacizumab and PARP inhibitors (PARPi) monotherapy are alternative options proficient (HRp) population. However, there no direct comparison between two therapeutic in previous studies. <h3>Methodology</h3> We retrospectively analyzed 84 HRp...